COMPETE-Trial
A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR pos.), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). 177Lu-edotreotide vs. everolimus in GEP-NET (COMPETE-Trial)
III
interventionell
International
177Lu-edotreotide
Status: Rekrutierung beendet
Zeitraum
2017
2022
Zentren
60
64
Keine Zentren gesucht
Patienten
300
324
21.10.2022
Klinische Settings
palliativ
Identifier
AIO-NET-0417/ass
AIO-NET-0417/ass
2016-001897-13
Kontakt
Leitung
Prof. Dr. Wolfgang Weber
Ansprechpartner*in
Dr. Nicolas Schneider / Amanda Rotger, MD
E-Mail info-solucin@itm-radiopharma.com